根据美国证监会最新文件披露,Sensei Biotherapeutics公司已正式注册2490万股普通股,这些股票将由售股股东进行二次转售。此次注册为现有股东提供了在公开市场出售其持股的通道,涉及股份数量较大,预计将对公司股票的市场流通性产生显著影响。
根据美国证监会最新文件披露,Sensei Biotherapeutics公司已正式注册2490万股普通股,这些股票将由售股股东进行二次转售。此次注册为现有股东提供了在公开市场出售其持股的通道,涉及股份数量较大,预计将对公司股票的市场流通性产生显著影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.